Related Experiment Video
Updated: Jul 18, 2026
07:56
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
Published on: August 11, 2021
The norepinephrine transporter and pheochromocytoma
Susannah Cleary1, Jacqueline K Phillips
1Division of Health Sciences, Murdoch University, South Street, MURDOCH, 6150, Perth, Western Australia, Australia.
Annals of the New York Academy of Sciences
|November 15, 2006
Summary
Pheochromocytomas, rare tumors, involve the norepinephrine transporter (NET). Strategies to enhance NET activity are explored for improved diagnostic and therapeutic use of 131I-MIBG.
Area of Science:
- Neuroendocrinology
- Oncology
- Molecular Biology
Background:
- Pheochromocytomas are rare neuroendocrine tumors synthesizing excess catecholamines.
- These tumors express the norepinephrine transporter (NET), crucial for 131I-MIBG uptake.
- 131I-MIBG is used for diagnosis and is being trialed for pheochromocytoma treatment.
Purpose of the Study:
- To review the role of NET in pheochromocytoma.
- To explore strategies for enhancing NET activity for improved 131I-MIBG therapy.
- To discuss NET regulation and novel therapeutic targets.
Main Methods:
- Review of existing literature on pheochromocytoma, NET, and 131I-MIBG.
- Discussion of chemotherapeutic agents (cisplatin, doxorubicin) in enhancing NET activity.
- Exploration of protein-protein interactions involving NET.
Main Results:
- NET expression levels vary, limiting consistent 131I-MIBG incorporation.
- Chemotherapeutic agents are investigated for their potential to increase NET functional activity.
- Novel protein-protein interactions, like with syntaxin 1A, are potential therapeutic avenues.
Conclusions:
- Enhancing NET activity is key to improving 131I-MIBG efficacy in pheochromocytoma.
- Targeting NET regulation and interactions may offer innovative therapeutic strategies.
- Further research into NET modulation is warranted for better patient outcomes.
Related Concept Videos
01:27Adrenergic Neurons: Neurotransmission
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:30Classification of Neurotransmitters
Neurotransmitters play a crucial role in the communication between neurons in the autonomic nervous system. Neurons in the autonomic nervous system can be cholinergic or adrenergic depending on the neurotransmitters synthesized. Cholinergic neurons use acetylcholine as their primary neurotransmitter. This includes all the preganglionic fibers of the sympathetic and pre- and postganglionic fibers of the parasympathetic nervous systems. In addition, neurons of the somatic nervous system also use...